Segall Bryant & Hamill LLC Buys 6,759 Shares of Zoetis Inc (ZTS)

Segall Bryant & Hamill LLC grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 1.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 641,637 shares of the company’s stock after purchasing an additional 6,759 shares during the quarter. Zoetis accounts for 1.2% of Segall Bryant & Hamill LLC’s investment portfolio, making the stock its 17th biggest position. Segall Bryant & Hamill LLC owned 0.13% of Zoetis worth $53,583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the business. Navellier & Associates Inc acquired a new position in shares of Zoetis in the fourth quarter worth about $606,000. Lombard Odier Asset Management Switzerland SA lifted its stake in shares of Zoetis by 13.8% in the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 279,676 shares of the company’s stock worth $20,148,000 after acquiring an additional 34,000 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Zoetis by 9.5% in the fourth quarter. Amalgamated Bank now owns 64,901 shares of the company’s stock worth $4,675,000 after acquiring an additional 5,633 shares in the last quarter. Westwood Holdings Group Inc. increased its holdings in Zoetis by 13.3% in the fourth quarter. Westwood Holdings Group Inc. now owns 65,133 shares of the company’s stock valued at $4,692,000 after buying an additional 7,632 shares during the last quarter. Finally, We Are One Seven LLC bought a new stake in Zoetis in the fourth quarter valued at about $120,000. Institutional investors own 90.12% of the company’s stock.

Shares of Zoetis traded up $0.32, hitting $87.68, during trading on Thursday, Marketbeat reports. 21,379 shares of the company traded hands, compared to its average volume of 2,609,786. The firm has a market capitalization of $42.13 billion, a PE ratio of 36.46, a price-to-earnings-growth ratio of 1.92 and a beta of 0.98. Zoetis Inc has a one year low of $59.50 and a one year high of $88.16. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51.

Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 earnings per share. analysts predict that Zoetis Inc will post 3.06 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

ZTS has been the subject of several research analyst reports. Cowen set a $85.00 price objective on Zoetis and gave the company a “buy” rating in a report on Thursday, February 15th. BMO Capital Markets set a $78.00 price objective on Zoetis and gave the company a “hold” rating in a report on Thursday, February 15th. Cantor Fitzgerald set a $90.00 price objective on Zoetis and gave the company a “buy” rating in a report on Thursday, February 15th. Bank of America boosted their price objective on Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $86.00 price objective (up from $84.00) on shares of Zoetis in a report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $84.25.

In other news, insider Kristin C. Peck sold 4,877 shares of the company’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the transaction, the insider now directly owns 42,652 shares of the company’s stock, valued at $3,559,735.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Heidi C. Chen sold 7,383 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $84.71, for a total value of $625,413.93. Following the transaction, the insider now directly owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The disclosure for this sale can be found here. Insiders have sold 12,277 shares of company stock valued at $1,033,899 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply